Drug intelligence / Profile preview

irinotecan + cisplatin + octreotide LAR

Development stage: Unknown
Lead developer: Yakult Honsha
Modality: Peptides, Small Molecules
Administration: Intravenous, Intramuscular

Overview

A combination treatment regimen consisting of irinotecan plus cisplatin (IP) chemotherapy followed by octreotide long-acting release (LAR) as maintenance therapy. This sequential approach has been studied in phase II clinical trials for advanced gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC). The regimen involves administering irinotecan (180mg/m²) and cisplatin (50mg/m²) on day 1, repeated every 2 weeks for up to six cycles, followed by octreotide LAR maintenance in patients without disease progression after chemotherapy.

Targets

TOP1 (DNA Topoisomerase I)SSTR5 (Somatostatin receptor 5)DNASSTR2 (Somatostatin receptor type 2)

Beyond the preview

Go deeper on irinotecan + cisplatin + octreotide LAR.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on irinotecan + cisplatin + octreotide LAR.

Explore the full profile